Prognostic value of the inflammatory prognostic index for postoperative recurrence in non-muscle-invasive bladder cancer
- 1Department of Urology, Xingtai People’s Hospital, Xingtai, Hebei China
Abstract
Background: To evaluate the prognostic value of the inflammatory prognostic index (IPI) for recurrence after transurethral resection of bladder tumour (TURBT) in non-muscle-invasive bladder cancer (NMIBC), and to compare its discriminatory performance with that of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR).
Methods: This retrospective study included 123 patients who underwent TURBT for primary NMIBC. The primary analysis evaluated IPI as a continuous variable. Optimal cut-off values were determined by receiver operating characteristic (ROC) curve analysis, recurrence-free survival (RFS) was characterised by Kaplan–Meier estimation, and independent predictors were identified by Cox proportional hazards regression. Bootstrap internal validation (B = 1000) was applied to quantify overfitting and assess cut-off stability.
Results: During a median follow-up of 36 months, 44 patients (35.8%) developed disease recurrence. Among the markers tested, IPI showed the largest area under the curve (AUC = 0.790, 95% CI 0.705–0.874) and performed better than NLR (AUC = 0.613), PLR (AUC = 0.523, 95% CI 0.418–0.629), and LMR (AUC = 0.624). When analysed as a continuous variable, each 0.1‑unit increase in IPI was associated with a 12% higher recurrence risk (HR 1.12, 95% CI 1.07–1.18, P < 0.001). For clinical interpretability, the optimal IPI cut-off was 0.223. In multivariable analysis, IPI ≥ 0.223 (HR 5.574, 95% CI 2.583–12.029, P < 0.001) and diabetes mellitus (HR 2.853, 95% CI 1.279–6.366, P = 0.010) were independently associated with recurrence. IPI remained significant after adjustment for either pathological grade or EAU risk group. A pre‑specified Fine–Gray competing‑risks sensitivity simulation gave similar results, suggesting that the association was not driven by overestimation of recurrence in the presence of hypothetical competing non‑cancer mortality (subdistribution HR 5.91, 95% CI 2.87–12.19; P < 0.001). Bootstrap validation suggested limited overfitting (bias-corrected C-statistic 0.790; optimism 0.020), a stable cut-off (bootstrap median 0.227, 95% CI 0.084–0.617), and good calibration (bias-corrected calibration slope 0.86, Brier score 0.091).
Conclusions: Preoperative IPI, analysed primarily as a continuous variable, was an independent predictor of recurrence after TURBT in patients with NMIBC, with each 0.1‑unit increase associated with a 12% higher recurrence risk. It showed better discriminatory accuracy than NLR, PLR, and LMR and may be a practical, low‑cost adjunct for risk stratification and individualized postoperative surveillance; the dichotomised threshold reported here is cohort‑specific and requires external validation.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12894-026-02301-3.
Related
- Preoperative Systemic Inflammatory Indices (SII, SIRI and PIV) Associated with Adverse Histology and 12-Month Recurrence After Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
- An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation
- Urinary dual-site proenkephalin (PENK) methylation testing for detection of high-grade or invasive recurrence during surveillance of non-muscle-invasive bladder cancer
- Preoperative Zinc Deficiency as a Novel Prognostic Predictor for Postoperative Recurrence in Hepatocellular Carcinoma
- Risk factors for recurrence after initial transurethral resection of bladder tumor in patients with non–muscle-invasive bladder cancer
BibTeX
@article{li2026prognostic,
title = {{Prognostic value of the inflammatory prognostic index for postoperative recurrence in non-muscle-invasive bladder cancer}},
author = {GengXu Li and Chao Tan and JunLi Wei and ShuBo Chen},
journal = {BMC Urology},
year = {2026},
month = aug,
doi = {10.1186/s12894-026-02301-3},
url = {https://doi.org/10.1186/s12894-026-02301-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic value of the inflammatory prognostic index for postoperative recurrence in non-muscle-invasive bladder cancer
AU - GengXu Li
AU - Chao Tan
AU - JunLi Wei
AU - ShuBo Chen
PY - 2026
DA - 2026/08/07
JO - BMC Urology
DO - 10.1186/s12894-026-02301-3
UR - https://doi.org/10.1186/s12894-026-02301-3
AB - Background: To evaluate the prognostic value of the inflammatory prognostic index (IPI) for recurrence after transurethral resection of bladder tumour (TURBT) in non-muscle-invasive bladder cancer (NMIBC), and to compare its discriminatory performance with that of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR). Methods: This retrospective study included 123 patients who underwent TURBT for primary NMIBC. The primary analysis evaluated IPI as a continuous variable. Optimal cut-off values were determined by receiver operating characteristic (ROC) curve analysis, recurrence-free survival (RFS) was characterised by Kaplan–Meier estimation, and independent predictors were identified by Cox proportional hazards regression. Bootstrap internal validation (B = 1000) was applied to quantify overfitting and assess cut-off stability. Results: During a median follow-up of 36 months, 44 patients (35.8%) developed disease recurrence. Among the markers tested, IPI showed the largest area under the curve (AUC = 0.790, 95% CI 0.705–0.874) and performed better than NLR (AUC = 0.613), PLR (AUC = 0.523, 95% CI 0.418–0.629), and LMR (AUC = 0.624). When analysed as a continuous variable, each 0.1‑unit increase in IPI was associated with a 12% higher recurrence risk (HR 1.12, 95% CI 1.07–1.18, P < 0.001). For clinical interpretability, the optimal IPI cut-off was 0.223. In multivariable analysis, IPI ≥ 0.223 (HR 5.574, 95% CI 2.583–12.029, P < 0.001) and diabetes mellitus (HR 2.853, 95% CI 1.279–6.366, P = 0.010) were independently associated with recurrence. IPI remained significant after adjustment for either pathological grade or EAU risk group. A pre‑specified Fine–Gray competing‑risks sensitivity simulation gave similar results, suggesting that the association was not driven by overestimation of recurrence in the presence of hypothetical competing non‑cancer mortality (subdistribution HR 5.91, 95% CI 2.87–12.19; P < 0.001). Bootstrap validation suggested limited overfitting (bias-corrected C-statistic 0.790; optimism 0.020), a stable cut-off (bootstrap median 0.227, 95% CI 0.084–0.617), and good calibration (bias-corrected calibration slope 0.86, Brier score 0.091). Conclusions: Preoperative IPI, analysed primarily as a continuous variable, was an independent predictor of recurrence after TURBT in patients with NMIBC, with each 0.1‑unit increase associated with a 12% higher recurrence risk. It showed better discriminatory accuracy than NLR, PLR, and LMR and may be a practical, low‑cost adjunct for risk stratification and individualized postoperative surveillance; the dichotomised threshold reported here is cohort‑specific and requires external validation. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12894-026-02301-3.
SN - 1471-2490
ER -